Evidence map›Paper›PMID 38491176›Full record

ArticleCommunications medicine2024

Improved measurement of disease progression in people living with early Parkinson's disease using digital health technologies.

Matthew D Czech, Darryl Badley, Liuqing Yang, Jie Shen, Michelle Crouthamel, Tairmae Kangarloo, E Ray Dorsey, Jamie L Adams, Josh D Cosman

Abstract read
In one paragraph

Article in Communications medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. What's in a name? reframing advanced Parkinson's disease as a multidimensional state.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matthew D CzechAbbVie, North Chicago, IL, USA. Matt.Czech@abbvie.com.ORCID http://orcid.org/0000-0001-9954-7003
Darryl BadleyAbbVie, North Chicago, IL, USA.
Liuqing YangAbbVie, North Chicago, IL, USA.
Jie ShenAbbVie, North Chicago, IL, USA.
Michelle CrouthamelAbbVie, North Chicago, IL, USA.ORCID http://orcid.org/0000-0001-6786-2658
Tairmae KangarlooTakeda Pharmaceutical Company Limited, Cambridge, MA, USA.
E Ray DorseyUniversity of Rochester Medical Center, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-5140-1248
Jamie L AdamsUniversity of Rochester Medical Center, Rochester, NY, USA.
Josh D CosmanAbbVie, North Chicago, IL, USA.ORCID http://orcid.org/0000-0003-3320-4053

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDigital health technologies show promise for improving the measurement of Parkinson's disease in clinical research and trials. However, it is not clear whether digital measures demonstrate enhanced sensitivity to disease progression compared to traditional measurement approaches.

methodsTo this end, we develop a wearable sensor-based digital algorithm for deriving features of upper and lower-body bradykinesia and evaluate the sensitivity of digital measures to 1-year longitudinal progression using data from the WATCH-PD study, a multicenter, observational digital assessment study in participants with early, untreated Parkinson's disease. In total, 82 early, untreated Parkinson's disease participants and 50 age-matched controls were recruited and took part in a variety of motor tasks over the course of a 12-month period while wearing body-worn inertial sensors. We establish clinical validity of sensor-based digital measures by investigating convergent validity with appropriate clinical constructs, known groups validity by distinguishing patients from healthy volunteers, and test-retest reliability by comparing measurements between visits.

resultsWe demonstrate clinical validity of the digital measures, and importantly, superior sensitivity of digital measures for distinguishing 1-year longitudinal change in early-stage PD relative to corresponding clinical constructs.

conclusionsOur results demonstrate the potential of digital health technologies to enhance sensitivity to disease progression relative to existing measurement standards and may constitute the basis for use as drug development tools in clinical research.

Identifiers

PMID38491176
PMCPMC10942994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.